Drug intelligence / Profile preview

ADX-246

Development stage: Unknown
Lead developer: Aldeyra Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ADX-246 is an orally administered, next-generation small molecule RASP (Reactive Aldehyde Species) modulator developed by Aldeyra Therapeutics. It is an analog of ADX-629 and is designed to treat immune-mediated systemic diseases thought to be caused or exacerbated by pro-inflammatory RASP. The drug is expected to initiate clinical testing in the first half of 2024 in a Phase 1/2 trial involving healthy volunteers and patients with atopic dermatitis. By modulating RASP, ADX-246 aims to reduce inflammation associated with various immune-mediated conditions[1][2][3][4][5][6].

Beyond the preview

Go deeper on ADX-246.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADX-246.

Explore the full profile